Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Holdings Boosted by Wealth Enhancement Advisory Services LLC

Wealth Enhancement Advisory Services LLC boosted its position in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 56.2% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 6,454 shares of the biopharmaceutical company's stock after purchasing an additional 2,323 shares during the period. Wealth Enhancement Advisory Services LLC's holdings in Alnylam Pharmaceuticals were worth $1,775,000 at the end of the most recent reporting period.

Other large investors have also added to or reduced their stakes in the company. Plato Investment Management Ltd grew its stake in shares of Alnylam Pharmaceuticals by 2,666.3% during the first quarter. Plato Investment Management Ltd now owns 4,509 shares of the biopharmaceutical company's stock valued at $674,000 after acquiring an additional 4,346 shares in the last quarter. Diversified Trust Co acquired a new stake in Alnylam Pharmaceuticals during the 2nd quarter valued at approximately $1,210,000. Headlands Technologies LLC purchased a new stake in Alnylam Pharmaceuticals during the 1st quarter worth approximately $471,000. Breakwater Capital Group acquired a new position in shares of Alnylam Pharmaceuticals in the 2nd quarter valued at approximately $249,000. Finally, Price T Rowe Associates Inc. MD boosted its stake in shares of Alnylam Pharmaceuticals by 5.8% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 3,685,753 shares of the biopharmaceutical company's stock valued at $550,837,000 after buying an additional 201,784 shares during the last quarter. 92.97% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of brokerages recently issued reports on ALNY. Royal Bank of Canada restated an "outperform" rating and issued a $300.00 price target on shares of Alnylam Pharmaceuticals in a research note on Friday. Needham & Company LLC restated a "buy" rating and issued a $320.00 target price on shares of Alnylam Pharmaceuticals in a research note on Friday. Bank of America increased their price target on shares of Alnylam Pharmaceuticals from $307.00 to $314.00 and gave the stock a "buy" rating in a research report on Monday, October 14th. Cantor Fitzgerald reissued a "neutral" rating and issued a $220.00 price objective on shares of Alnylam Pharmaceuticals in a report on Friday, October 11th. Finally, Wells Fargo & Company increased their target price on Alnylam Pharmaceuticals from $207.00 to $233.00 and gave the stock an "equal weight" rating in a report on Friday, August 2nd. Six equities research analysts have rated the stock with a hold rating and nineteen have assigned a buy rating to the company's stock. According to data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $294.50.

Insider Transactions at Alnylam Pharmaceuticals

In related news, Director Dennis A. Ausiello sold 20,250 shares of the firm's stock in a transaction dated Tuesday, August 6th. The stock was sold at an average price of $262.00, for a total transaction of $5,305,500.00. Following the completion of the transaction, the director now owns 136 shares of the company's stock, valued at $35,632. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. In other news, CEO Yvonne Greenstreet sold 15,000 shares of the firm's stock in a transaction on Tuesday, August 20th. The stock was sold at an average price of $280.00, for a total transaction of $4,200,000.00. Following the completion of the sale, the chief executive officer now directly owns 73,441 shares of the company's stock, valued at $20,563,480. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Dennis A. Ausiello sold 20,250 shares of Alnylam Pharmaceuticals stock in a transaction on Tuesday, August 6th. The stock was sold at an average price of $262.00, for a total value of $5,305,500.00. Following the completion of the transaction, the director now owns 136 shares in the company, valued at $35,632. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 1.50% of the company's stock.

Alnylam Pharmaceuticals Trading Down 1.4 %

ALNY stock traded down $3.96 during trading on Monday, hitting $269.95. The company had a trading volume of 776,305 shares, compared to its average volume of 870,820. The business has a 50 day moving average of $274.61 and a 200 day moving average of $227.00. The firm has a market capitalization of $34.66 billion, a price-to-earnings ratio of -103.03 and a beta of 0.39. Alnylam Pharmaceuticals, Inc. has a fifty-two week low of $141.98 and a fifty-two week high of $304.39.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last posted its quarterly earnings data on Thursday, October 31st. The biopharmaceutical company reported ($0.87) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.51) by ($0.36). The firm had revenue of $500.90 million for the quarter, compared to analyst estimates of $532.91 million. During the same period in the previous year, the business earned $1.15 EPS. Alnylam Pharmaceuticals's quarterly revenue was down 33.3% on a year-over-year basis. As a group, equities analysts predict that Alnylam Pharmaceuticals, Inc. will post -2.74 EPS for the current year.

Alnylam Pharmaceuticals Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.